Waterloo, Iowa Clinical Trials

A listing of Waterloo, Iowa clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, …

folfiri
platelet count
open biopsy
major surgery
vitamin d
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 65 views
  • 13 Jun, 2021
  • +947 other locations
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

alzheimer's disease
florbetapir
flortaucipir
positron emission tomography
mini-mental state examination
Northeast Iowa Medical Education
 (2.7 away) Contact site
  • 79 views
  • 29 May, 2021
  • +379 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

epidermal growth factor receptor
erbb2
inflammatory breast cancer
epirubicin
HER2
MercyOne Waterloo Cancer Center ( Site 0016)
 (1.5 away) Contact site
  • 188 views
  • 13 Jun, 2021
  • +285 other locations
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to …

metastatic cancer
kidney function test
anorexia
anamorelin
renal function
MercyOne Waterloo Cancer Center
 (1.5 away) Contact site
  • 197 views
  • 31 May, 2021
  • +72 other locations
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with …

primary cancer
dexamethasone
vomiting
emetics
metastasis
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 109 views
  • 13 Jun, 2021
  • +586 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

arterial disease
stemi
stroke
diabetes
infarct
8400904 - Northeast Iowa Medical Education Foundation
 (1.5 away) Contact site
  • 1118 views
  • 13 Jun, 2021
  • +3422 other locations
S0820 Adenoma and Second Primary Prevention Trial

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

unstable angina
aspirin
anticoagulants
adenoma
rectal carcinoma
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 2518 views
  • 03 Mar, 2021
  • +1033 other locations
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. …

carboplatin
ROS1
brain metastases
systemic chemotherapy
cancer treatment
MercyOne Waterloo Medical Center
 (2.7 away) Contact site
  • 206 views
  • 13 Jun, 2021
  • +823 other locations
Testing The Addition of a New Anti-cancer Drug Venetoclax to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated Older Patients With Chronic Lymphocytic Leukemia

This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment. The addition of venetoclax to the usual treatment might prevent chronic lymphocytic leukemia from returning. This trial also will …

lymphadenopathy
lymphocytosis
fever
platelet count
fatigue
MercyOne Waterloo Medical Center
 (1.5 away) Contact site
  • 374 views
  • 13 Jun, 2021
  • +735 other locations